NEWTOWN, Pa., Oct. 27 /PRNewswire/ — Essential Pharmaceuticals,
LLC, a private company dedicated to providing specialty reagents
and solutions to the life sciences market, announced today that the
Company will commence sales and distribution of three distinct
animal-component-free products: serum replacement, cryopreservation
and clinical pathology media, formerly sold under the
LiforCell® name:
- Cell-Ess™ Serum Replacement cell culture medium,
- Cryo-Ess™ cryopreservation medium, and
- Clin-Ess™ transportation medium.
“The quality and consistency of Cell-Ess, Cryo-Ess and Clin-Ess
gives scientists the confidence to conduct their research without
testing each new serum lot purchased, resulting in improved
laboratory efficiency and valuable cost savings,” said Allan Weber,
chief executive officer of Essential Pharmaceuticals.
“Moreover, we believe that the characteristics of these media
products offer important clinical benefits, making Cell-Ess the
ideal choice for use in the cutting edge areas of stem cell, cancer
and vaccine research, and Clin-Ess in the preservation of limbs and
organs for surgical applications.”
The Cell-Ess, Cryo-Ess and Clin-Ess family offers researchers
the advantage of superior performance compared to fetal bovine
serum. They are free of all animal components and dimethyl
sulfoxide (DSMO), do not crystallize or form ice during the thawing
process, resulting in less DNA and RNA degradation and fewer
artifacts than those preserved using conventional methods. Further,
they have demonstrated synthetic reproducibility with no lot-to-lot
variability.
Essential Pharmaceuticals acquired exclusive worldwide rights to
these media products, originally the LiforCell® family of
products, from Lifeblood Medical, Inc. These cell culture and
cryopreservation products
‘/>”/>
